CLEVELAND HEARTLAB, INC.
CLEVELAND, OH

Cleveland HeartLab, Inc. is a pioneering medical testing company specializing in innovative biomarker technologies focused on cardiovascular risk assessment. Founded on September 9, 2011, and incorporated as FORP (Foreign) in Florida, Cleveland HeartLab offers advanced inflammation and lipid testing through its CAP-accredited and CLIA-certified laboratories. The company's mission is to be the premier provider of cardiovascular diagnostics by combining traditional cholesterol measurements with cutting-edge inflammatory markers to enhance risk prediction. Using a scientifically-proven approach that integrates peer-reviewed biomarker-based tests, Cleveland HeartLab assists healthcare providers across North America, Europe, and Asia in managing and preventing heart disease. Their advanced lipid profiling goes beyond standard panels by assessing particle number and size, providing more detailed cardiovascular risk insights. Cleveland HeartLab’s testing methods have garnered significant attention, underscored by research indicating their potential to reduce major adverse cardiac events and prevent substantial healthcare costs annually. Additionally, Cleveland HeartLab is committed to education through CME-accredited events, offering valuable resources for healthcare professionals on novel biomarker applications. Headquartered in Secaucus, NJ, with filing number F11000003658 listed in Leon County, FL, Cleveland HeartLab’s leadership includes President Mark E Delaney, Vice President Sandip R Patel, and Secretary Sean D Mersten. For more information, inquiries can be directed to their mailing address at 500 Plaza Drive, or via phones (866) 358-9828, (216) 426-6085, and others. Their website is www.clevelandheartlab.com.